Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATALANTa: Alvelestat in Alpha-1 Antitrypsin Deficiency
NCT03679598Phase 2Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Apr 2019
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alvelestat in alpha-1 antitrypsin deficiency (AATD), sponsored by University of Alabama at Birmingham. Started Apr 2019; status: completed.
02
Drugs
alvelestat
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT03679598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03679598.